Browse SUPT6H

Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF14878 Death-like domain of SPT6
PF14635 Helix-hairpin-helix motif
PF14641 Helix-turn-helix DNA-binding domain of SPT6
PF00575 S1 RNA binding domain
PF14633 SH2 domain
PF14632 Acidic N-terminal SPT6
PF14639 Holliday-junction resolvase-like of SPT6
Function

Transcription elongation factor which binds histone H3 and plays a key role in the regulation of transcription elongation and mRNA processing. Enhances the transcription elongation by RNA polymerase II (RNAPII) and is also required for the efficient activation of transcriptional elongation by the HIV-1 nuclear transcriptional activator, Tat. Besides chaperoning histones in transcription, acts to transport and splice mRNA by forming a complex with IWS1 and the C-terminal domain (CTD) of the RNAPII subunit RPB1 (POLR2A). The SUPT6H:IWS1:CTD complex recruits mRNA export factors (ALYREF/THOC4, EXOSC10) as well as histone modifying enzymes (such as SETD2), to ensure proper mRNA splicing, efficient mRNA export and elongation-coupled H3K36 methylation, a signature chromatin mark of active transcription. SUPT6H via its association with SETD1A, regulates both class-switch recombination and somatic hypermutation through formation of H3K4me3 epigenetic marks on activation-induced cytidine deaminase (AICDA) target loci. Promotes the activation of the myogenic gene program by entailing erasure of the repressive H3K27me3 epigenetic mark through stabilization of the chromatin interaction of the H3K27 demethylase KDM6A.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002694 regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0006310 DNA recombination
GO:0006338 chromatin remodeling
GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006397 mRNA processing
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006406 mRNA export from nucleus
GO:0006479 protein methylation
GO:0006913 nucleocytoplasmic transport
GO:0008213 protein alkylation
GO:0008380 RNA splicing
GO:0010793 regulation of mRNA export from nucleus
GO:0015931 nucleobase-containing compound transport
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018022 peptidyl-lysine methylation
GO:0018205 peptidyl-lysine modification
GO:0019724 B cell mediated immunity
GO:0031056 regulation of histone modification
GO:0031057 negative regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0031061 negative regulation of histone methylation
GO:0032239 regulation of nucleobase-containing compound transport
GO:0032259 methylation
GO:0032386 regulation of intracellular transport
GO:0032784 regulation of DNA-templated transcription, elongation
GO:0032786 positive regulation of DNA-templated transcription, elongation
GO:0032968 positive regulation of transcription elongation from RNA polymerase II promoter
GO:0034243 regulation of transcription elongation from RNA polymerase II promoter
GO:0034968 histone lysine methylation
GO:0042113 B cell activation
GO:0042692 muscle cell differentiation
GO:0043414 macromolecule methylation
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046831 regulation of RNA export from nucleus
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0050684 regulation of mRNA processing
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0051028 mRNA transport
GO:0051052 regulation of DNA metabolic process
GO:0051147 regulation of muscle cell differentiation
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
GO:0051249 regulation of lymphocyte activation
GO:0061085 regulation of histone H3-K27 methylation
GO:0061086 negative regulation of histone H3-K27 methylation
GO:0070734 histone H3-K27 methylation
GO:0071166 ribonucleoprotein complex localization
GO:0071426 ribonucleoprotein complex export from nucleus
GO:0071427 mRNA-containing ribonucleoprotein complex export from nucleus
GO:1902275 regulation of chromatin organization
GO:1903311 regulation of mRNA metabolic process
GO:1905268 negative regulation of chromatin organization
GO:2000197 regulation of ribonucleoprotein complex localization
Molecular Function GO:0042393 histone binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-112387: Elongation arrest and recovery
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-74160: Gene Expression
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SUPT6H and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SUPT6H in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.97 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SUPT6H in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.270.139
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.320.882
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2350.878
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2180.431
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1140.968
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3550.924
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2120.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2010.913
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1710.936
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3170.841
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7990.722
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0510.278
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SUPT6H in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SUPT6H. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SUPT6H. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SUPT6H.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SUPT6H. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SUPT6H expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SUPT6H and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSUPT6H
NameSPT6 homolog, histone chaperone
Aliases KIAA0162; SPT6H; suppressor of Ty (S.cerevisiae) 6 homolog; suppressor of Ty 6 homolog (S. cerevisiae); SPT6 ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SUPT6H collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.